Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186316 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00186316: Completed Phase 1 study, sponsored by Stanford University.
NCT00186316 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186316, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
Interventions
- BIOLOGICAL Idiotype-pulsed allogeneic dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186316
The ClinicalTrials.gov registry entry for NCT00186316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idiotype-pulsed allogeneic dendritic cells is the first listed.
NCT00186316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186316 about?
NCT00186316 is a clinical study titled "Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells". Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
What is the current status of trial NCT00186316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00186316?
The interventions under investigation include: Idiotype-pulsed allogeneic dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00186316?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.